Interaction of septin 7 and DOCK8 in equine lymphocytes reveals novel insights into signaling pathways associated with autoimmunity

Melanie Schauer[1], Kristina J H Kleinwort[1], Roxane L Degroote[1], Carmen Wiedemann[1], Elisabeth Kremmer[2], Stefanie M Hauck[3], Cornelia A Deeg[1*]

[1] Chair for Animal Physiology, Department of Veterinary Sciences, LMU Munich, 80539 Munich, Germany

[2] Institute for Molecular Immunology, Helmholtz Center Munich, German Research Center for Environmental Health GmbH, 81377 Munich, Germany

[3] Research Unit Protein Science, Helmholtz Center Munich, German Research Center for Environmental Health GmbH, 80939 Munich, Germany

*Corresponding author:

Cornelia A. Deeg, Chair for Animal Physiology, Department of Veterinary Sciences, LMU Munich, Veterinärstr. 13, D-80539 Munich. E-mail: Cornelia.Deeg@lmu.de,

Phone: + 49 (0)89–21802551

ABSTRACT

The GTP-binding protein septin 7 is involved in various cellular processes, including cytoskeleton organization, migration and the regulation of cell shape. Septin 7 function in lymphocytes, however, is poorly characterized. Since the intracellular signaling role of septin 7 is dependent on its interaction network, interaction proteomics was applied to attain novel knowledge about septin 7 function in hematopoietic cells. Our previous finding of decreased septin 7 expression in peripheral blood-derived lymphocytes in ERU, a spontaneous animal model for autoimmune uveitis in man, extended the role of septin 7 to a potential key player in autoimmunity. Here, we revealed novel insights into septin 7 function by identification of DOCK8 as an interaction partner in primary blood derived lymphocytes. Since DOCK8 is associated with important immune functions, our finding of significantly decreased DOCK8 expression and altered DOCK8 interaction network in ERU might explain changes in immune response and shows the contribution of DOCK8 in pathomechanisms of spontaneous autoimmune diseases. Moreover, our analyses revealed insights in DOCK8 function, by identifying the signal transducer ILK as a novel DOCK8 interactor in lymphocytes. Our finding of the enhanced enrichment of ILK in ERU cases indicates a deviant influence of DOCK8 on inter- and intracellular signaling in autoimmune disease.

INTRODUCTION

Septins are GTP-binding cytoskeletal proteins involved in various cellular processes, including cytokinesis, membrane dynamics and regulation of cell shape [1,2]. They are highly conserved from yeast to humans. One unique feature of septins is the ability to self-assemble and form filaments that serve as scaffolds for protein recruitment [3]. The assembly of septin filaments consists of hexamers and octamers which are formed by septin subunits [4], all including the essential group member septin 7 [5,6]. Due to its pivotal role in the formation of septin filaments, the depletion of septin 7 leads to destabilization of the core septin cytoskeleton in mammalian cells [1].

We previously found septin 7 protein downregulated in $CD4^+$ T cells of equine recurrent uveitis (ERU) cases [7]. ERU represents the only spontaneous model for autoimmune uveitis in humans [8] and is characterized by remitting painful attacks of the inner eye, caused by infiltration of immune cells [9], eventually leading to vision loss. During uveitic attacks, autoreactive $CD4^+$ T-lymphocytes cross the blood-retina-barrier, infiltrating ciliary body, choroid and retina and destruct retinal tissue [9,10]. The initiating pathomechanism, causing these peripheral lymphocytes to target intraocular tissue is still poorly understood. One possible explanation might be their altered septin 7 expression level leading to changed migratory behavior and deviant activation of T cells [7]. In murine primary T cells, knock-down of septin 7 impaired the motility of these cells and led to a significantly higher transmigration rate through small pores [11]. Since migration of T cells into the eye is the key driver of pathology in ERU [12,13], decreased septin 7 expression might have the same effect, pointing to a pivotal role of septin 7 in cellular processes that regulate immune functions such as cell signaling or cell migration.

However, the impact of expression changes or functional deviations of septin 7 in lymphocytes in course of autoimmune disease was not described to date. Since interaction networks of

septins are functionally crucial due to their signal-mediating role in cellular processes [14], unraveling the septin 7 interactome in lymphocytes could contribute to a better understanding of septin 7 function. Therefore, we investigated septin 7 protein networks in primary blood-derived lymphocytes (PBL) with a special focus on immune response related candidates and their functions in autoimmune reactions.

RESULTS

Detection of DOCK8 as a novel interaction partner of septin 7

Since the impact of changes in septin 7 protein levels in lymphocytes is yet to be unraveled, we further characterized septin 7 function by identifying septin 7-interacting partners in PBL of healthy cases with immune precipitation, followed by label-free LC-MS/MS mass spectrometry. A total of 20 septin 7 interacting proteins could be detected in this experiment (Table 1). Amongst these, known septin 7 interactors from studies in other models were identified, e.g. septin 2, septin 6 and the small GTPase CDc42 [15,16]. Additionally, we detected 10 novel septin 7 interactors in PBL, not described before to our knowledge (Table 1).

One of these interaction partners, dedicator of cytokinesis 8 (DOCK8), regulates various immune functions in lymphocytes [17-19]. DOCK8 was shown to be involved in immune synapse formation, lymphocyte migration and organization of cell shape [18]. We confirmed DOCK8 as a novel septin 7 interaction partner by immunoprecipitation and western blot in PBL (Figure 1A). In the reverse experiment, immunoprecipitation of DOCK8 clearly co-precipitated septin 7. Since this suggested as yet unknown, we were interested in potential changes of DOCK8 protein levels associated to this autoimmune disease.

DOCK8 was highly expressed in all lymphocyte subsets

To gain further insights in physiological DOCK8 expression pattern, we analyzed DOCK8 expression levels in $CD4^+$ T cells, $CD8^+$ T cells and in B cells of horses using flow cytometry. DOCK8 was expressed in all lymphocyte subsets with high intensity (Figure 2), which points to similarities across species, because this was also shown in mice and man [17]. The protein level of DOCK8 in B cells was significantly higher as compared to T cells (two-fold; Figure 2). This DOCK8 expression pattern was never described in other species, since proteomic data

generated in human lymphocytes showed equal expression pattern of DOCK8 in T cells and B cells [20].

DOCK8 expression in lymphocytes was decreased in autoimmune cases

Next, we analyzed DOCK8 protein levels in lymphocytes of autoimmune cases to detect possible differences in expression. A highly significant (*** = $p \leq 0.001$) decrease of DOCK8 expression to 63% (± 28.5% standard deviation (SD)) in ERU compared to healthy controls (100% ± 38.3% SD) was detected by western blot (Figure 3). To determine in which cell population downregulation was predominant, we further characterized changes in $CD4^+$ and $CD8^+$ T cells as well as in B cells by flow cytometry. DOCK8 was also present in all lymphocyte subsets of ERU cases, but with considerably decreased levels (geo MFI) in all lymphocyte subsets analyzed (Figure 3). In T°cells, differences in DOCK8 protein levels were not significant. In B cells, however, the level of DOCK8 was significantly (* = $p \leq 0.05$) decreased to 57% ± 42% SD in PBL of ERU cases, compared to healthy controls (100% ± 45% SD).

Unraveling different modes of DOCK8 action in physiological immune response and autoimmunity

Since the functional impact of differential DOCK8 protein levels in autoimmune diseases is unknown, we further investigated potential differences in protein-protein-interaction network of DOCK8 in healthy and autoimmune phenotypes with interaction proteomics. We identified a total of 259 potential DOCK8 interaction partners, that were detectable in all lymphocyte samples analyzed. Interestingly, we could detect remarkable differences in DOCK8-protein enrichment patterns between lymphocytes of healthy and autoimmune case groups. Amongst the 259 interacting proteins, 53 proteins were enriched in both phenotypes, whereas 28 proteins

showed enhanced enrichment in lymphocytes of healthy controls and 178 proteins were enriched in lymphocytes of autoimmune cases.

To determine whether DOCK8 functions through different signal transduction pathways in controls and diseased cases, we analyzed DOCK8 interaction network for enrichment of canonical pathways with gene ranker in both phenotypes. Interestingly, we found different signaling pathways with enhanced enrichment in control lymphocytes and in ERU cases (Table 2; Table 3). In PBL of healthy controls, the pathways "ARP2 Actin Related Protein 2 Homolog", "Small GTP-binding Protein RAC" and "Myosin light chain kinase" were enriched (Table 2). This differed in lymphocytes of ERU cases, where only the pathway "ARP2 Actin Related Protein 2 Homolog" was concurrently enriched (Table 3). Then the two signaling pathways "Integrin" and "Cofilin" were among the top 3 DOCK8-interacting signaling pathways enriched in PBL of autoimmune cases (Table 3). Since proteins comprised in integrin signaling pathway are associated with a wide range of important immune functions, as cell migration or survival, we were especially interested in the role of DOCK8-interactors associated to integrin signaling. This revealed proteins, as talin 1 and integrin-linked kinase (ILK) (Table 3), which we previously found involved in inflammatory processes in ERU cases [21,22].

Enhanced expression of ILK, a novel DOCK8 interaction partner in autoimmune cases

Since the role of ILK in autoimmunity is yet to be unraveled, we further characterized the role of ILK in PBL of controls and autoimmune cases. Due to its crucial involvement in signal transduction, chemotaxis and regulation of cell survival [23], ILK represents a potential key player in ERU. By comparing ILK protein levels in lymphocytes of healthy and ERU cases, we detected a significant increase of ILK protein expression in PBL of diseased specimen (Figure 4A).

Lymphocytes with increased ILK expression have higher survival rate

Since ILK was shown to be essential for various cellular functions including the regulation of survival in murine lymphocytes [23], we hypothesized that increased expression intensity of ILK in spontaneous autoimmune cases might result in a higher survival rate of respective lymphocytes. This could affect immune tolerance and provoke autoaggressive immune reaction. Therefore, we investigated apoptotic rates of lymphocytes of healthy and autoimmune cases, showing a constitutive differential ILK expression level. Increased ILK protein level in lymphocytes of diseased specimen coincided with a significantly (** = $p \leq 0.01$) reduced apoptosis rate of these cells (Figure 4B). Whereas PBL of control cases had an average apoptosis rate of 50.6% ± 10.8% SD; apoptosis rate of autoimmune cases was only 29.7% ± 5.8% SD. Necrosis of lymphocytes was equally low in both phenotypes (< 1%) (Figure 4C).

DISCUSSION

The aim of our study was to extend the knowledge about the role of septin 7 in lymphocytes and in the context of a spontaneous autoimmune disease. We previously observed decreased levels of septin 7 in lymphocytes isolated from ERU cases [7]. Since functional impact of reduced septin 7 levels in lymphocytes and, more generally, in horse cells, was unknown, we chose a protein-protein interaction screening approach to identify proteins potentially relevant for signal transduction pathways triggered by septin 7. We identified a total of 20 septin 7 interacting proteins from primary PBL. Nine of these proteins were previously suggested as septin 7 interactors (supplemental table 1), however identified mostly in yeast cells using septin 7 plasmid-driven overexpression [24]. Since our approach based on immunoprecipitation from native cells, the confirmation of previously described interactors suggests similar core units of the septin interactome across cell types and species. Among those reconfirmed septin 7 interactors were proteins shown to be involved in cytokinesis and cell migration in other models, e.g. septin 2 and septin 6 [11,24] (table 1).

Furthermore, we detected 10 proteins interacting with septin 7 in lymphocytes, which were previously unknown. Amongst those, especially the identification of DOCK8 as a novel septin 7 interaction partner was a promising finding that could help to elucidate pathomechanisms in autoimmune diseases in our opinion. Like septin 7, DOCK8 is involved in the organization of actin cytoskeleton and regulates the structural integrity during immune cell trafficking [18,25]. Similar to septin 7 [7], DOCK8 levels were reduced in lymphocytes of ERU cases (Figure 3) strengthening the functional overlap between these two molecules, which might affect the regulation of immune cell migration. Moreover, investigations on life-threatening DOCK8-deficiency in humans have pointed to a crucial role of DOCK8 in the immune system, since the loss of DOCK8 function in lymphocytes leads to impaired immunity and an increased disposition for recurrent infections [26]. Particularly, DOCK8 regulates several functions of

T cells, natural killer (NK) cells and B cells in humans and mice, by being essential for survival, immune synapse formation and activation of lymphocytes [17,19,27,28]. This critical involvement of DOCK8 in immune cell functions could in turn determine the role of septin 7 in the immune system, considering the fact that septins act as potential scaffolding platforms for interacting proteins, which mediate cellular functions.

Since the in-depth expression analysis of these interacting proteins is of considerable value for approaching cellular and molecular septin 7 functions, we characterized the expression pattern of DOCK8 in primary blood-derived lymphocytes (Figure 2). In controls, high levels of DOCK8 were detected in all lymphocytes, comparable to humans and mice [29], pointing to a conserved role of DOCK8 in immune cells across species. However, we could detect a difference of DOCK8 protein levels between T cells and B cells in PBL of healthy controls. Whereas in lymphocytes of healthy humans, equal protein levels of DOCK8 were present in T cells and B cells [20], our analysis revealed significant 2-fold higher (* = $p \leq 0.05$) protein levels of DOCK8 in B cells compared to levels in $CD4^+$ T cells (Figure 2).

Further, in our study DOCK8 levels significantly decreased in lymphocytes of autoimmune cases compared to healthy controls (Figure 3). Since DOCK8 is involved in several cellular processes in the immune system [17,19,27,30], this significant decrease in lymphocytes of autoimmune cases might explain changes in the immune response in disease. So far, the effects of DOCK8 downregulation in a spontaneous autoimmune disease are not fully understood. However, in DOCK8-deficient individuals, a predisposition to autoimmune manifestations was observed, including vasculitis, hemolytic anemia and even one case of uveitis suspected to be of autoimmune origin [26,31,32]. Suggestions, explaining the susceptibility towards autoimmunity, included increased numbers of autoreactive antibodies due to decreased numbers of regulatory T cells (Tregs) and impaired peripheral B cell tolerance, which were determined in DOCK8-deficient individuals [33]. Interestingly, we previously detected autoantibodies to

uveitogenic autoantigens as cRALBP in sera of autoimmune cases [34,35]. Therefore, our findings of decreased DOCK8 protein levels might contribute to a better understanding of pathomechanisms in which autoantibodies are involved and let us presume possible changes in the differentiation of Tregs or B cell tolerance. However, in DOCK8-deficiency cases, presented with typical findings like eczema, eosinophilia and increased serum IgE, the median peripheral blood counts of Tregs were comparable to healthy controls [36]. These distinct findings indicate that more investigations are needed to unravel the impact of a decreased DOCK8 expression levels on the differentiation of Tregs in autoimmune diseases.

Since our findings pointed to a crucial role of DOCK8 in autoimmune diseases, we were interested in the potential functional changes of lymphocytes in autoimmunity, driven by DOCK8. By detecting remarkable differences in DOCK8 protein-protein-interactions in lymphocytes of healthy and autoimmune cases, we demonstrated that DOCK8 takes a deviant role in disease. Since DOCK8 interaction partners were differentially enriched in both phenotypes and in general, more interacting proteins were identified from autoimmune PBL (178 interaction partners), we hypothesized that DOCK8 contributes to a deviant inter- and intracellular signaling in disease, resulting in changed immune response. Thus, we focused on differences in signaling pathways driven by DOCK8 and revealed changes in integrin signaling, which were associated with autoimmunity (Table 3). Proteins comprised in integrin pathway as talin 1 and integrin-linked kinase (ILK) (Table 3) determine crucial cellular responses as adhesion, migration or survival [23,37] and we previously demonstrated their critical involvement in inflammatory processes of autoimmune cases in earlier studies [21,22,38]. Therefore, the enrichment of integrin pathway in lymphocytes of diseased specimen might explain autoreactive immune responses driven by DOCK8. Especially our finding of the DOCK8 interaction partner ILK, comprised in integrin pathway with enhanced enrichment in autoimmune cases (Table 3), reinforced this hypothesis, since this serine-threonine kinase

regulates several immune functions [39,40]. Interestingly, ILK was recently described to be specifically upregulated in PBL from horses with induced autoimmune uveitis during an acute uveitic attack [21], which implicates a direct correlation of ILK upregulation and autoaggressive reaction of lymphocytes. Thus, we suggest that the increased ILK expression in lymphocytes of spontaneous autoimmune cases promotes changes in immune responses resulting in autoreactivity of activated lymphocytes. So far, cellular mechanisms driven by ILK overexpression in lymphocytes are not fully elucidated. However, a competitive advantage in trafficking and survival was demonstrated in murine ILK-competent T cells, whereas thymocytes of T cell-specific knockout mice showed diminished survival, particularly a higher apoptosis rate and increased necrosis after stressing of these cells [23]. Since ILK serves as an upstream modulator of Akt, which mediates inhibition of apoptosis [41], the increased expression intensity of ILK in lymphocytes of autoimmune cases might result in higher survival, provoking insufficient deletion of autoreactive T-cells. Therefore, we determined apoptosis rate of primary blood-derived lymphocytes with spontaneously altered ILK expression (Figure 4). In lymphocytes of autoimmune cases, showing ILK overexpression, apoptosis rate decreased significantly compared to healthy specimen whereas necrosis was consistently negligible in both phenotypes (< 1%) (Figure 4), indicating a correlation between changed ILK expression and reduced apoptosis in ERU. These interesting findings will be profoundly analyzed in subsequent studies to elucidate the impact of divergent apoptotic behavior of cells on autoreactive immune responses in disease.

In summary, our findings provide deeper insight into interaction networks in lymphocytes and contribute to a better understanding of immune cell functions. Moreover, we gained information about the role of septin 7 and its novel interactor DOCK8 in autoimmune disease. We propose that the decreased expression levels of these potential key players in autoimmune uveitis and

the deviant signaling pathways driven by DOCK8 promote autoreactive inflammatory processes.

METHODS

Sample preparation

For this study, PBL of 20 healthy and 54 ERU cases were used. No experimental animals were used in this study. Horses were treated according to the ethical principles and guidelines for scientific experiments on animals according to the ARVO statement for the use of animals in Ophthalmic and Vision research. The local authority permitted withdrawal of blood samples (Regierung von Oberbayern; permit number: ROB-55.2Vet-2532.Vet_03-17-88).

In detail, mass spectrometric analysis of septin 7 interaction network was performed in PBL of a healthy control. Additionally, PBL of eight healthy horses were used for confirming septin 7 interaction partners by co-immunoprecipitation. Phenotyping DOCK8 expression in healthy controls and ERU horses was achieved by flow cytometric analysis of 13 controls and 12 ERU cases and by western blot analysis of 16 healthy and 36 ERU horses. PBL of three healthy and three ERU cases were used for co-immunoprecipitation of DOCK8 followed by mass spectrometric analysis. Expression analysis of ILK by western blot was performed in 17 controls and 34 ERU cases. Apoptosis and necrosis rates were investigated in four healthy and six ERU horses.

Equine venous blood samples were collected in tubes filled with heparin sodium 25.000 I.U. (Ratiopharm, Ulm, Germany) diluted in RPMI (PanBiotech, Aidenbach, Germany). PBL from plasma were isolated by density gradient centrifugation (room temperature (RT), 290 × g, 25 min, brake off) using Pancoll separation solution (PanBiotech). Lymphocytes were extracted from intermediate phase. Cells were either used immediately or stored at -20°C (lysate) or -80°C (vital cells).

Immunoprecipitation (IP) of interacting proteins

PBL derived from whole blood were lysed in IP-lysis-buffer (TBS containing 50 mM Tris and 150 mM NaCl, 2% CHAPS, Roche complete EDTA-free protease inhibitor) and protein concentration was determined by use of Bradford protein assay (Sigma-Aldrich, Taufkirchen, Germany). 40 µl of Protein G Sepharose Beads (GE Healthcare, Freiburg, Germany) per 1 mg protein were washed with IP-buffer diluted with TBS and incubated separately with rat anti-septin 7 antibody (clone 19A4, self-made monoclonal rat anti-septin 7 antibody, isotype IgG2c; neat), rabbit polyclonal anti-DOCK8 antibody (H-159, Santa Cruz, Heidelberg, Germany; 6 µg/ml) diluted in IP-buffer or respective isotype controls were used. Lysates were added to beads and incubated on a tube rotator over night at 4°C. Beads were washed with IP-lysis-buffer before immunoprecipitates were eluted by adding Laemmli-buffer.

Sample preparation for LC-MS/MS mass spectrometry

Laemmli eluates were diluted in TBS 1:4 and 10 µl 100 mM dithiothreitol was added for 30 min at 60°C. After cooling down, 100 µl UA-buffer (8 M urea + 1 M Tris-HCl pH 8.5 diluted in HPLC-grade water) was added. Eluates were transferred to 30 kDa cut-off centrifuge filters (Sartorius, Göttingen, Germany) and washed with 200 µl UA-buffer and with 100 µl ABC-buffer (50 mM NH_3HCO_3 diluted in HPLC-grade water). After washing, the proteins were subjected to proteolysis at RT for 2 h with 1 µg Lys-C in 50 µl ABC-buffer followed by addition of 1 µg trypsin in 10 µl of ABC-buffer and incubation at 37°C overnight. Peptides were collected by centrifugation and acidified with 0.5% trifluoroacetic acid.

Mass spectrometry for identification of interacting proteins

LC-MS/MS analyses were performed on an LTQ OrbitrapXL (Thermo Fisher Scientific, Bremen, Germany). Briefly, peptides were loaded onto an Ultimate3000 nano HPLC system (Dionex, Idstein, Germany) equipped with a nano trap column at a flow rate of 30 µl/min in

HPLC-buffer. Peptides were separated on a reversed phase chromatography over 140 min at a flow rate of 300 nl/min. For mass spectrometric analysis, a maximal injection time of 100 ms for MS spectra and 500 ms for MS/MS spectra was defined. MS spectra were recorded within a mass range from 200-2000 Da at a resolution of 60,000 full-width half-maximum. All ions which were selected for fragmentation (top 10 method) went through dynamic exclusion over 30 sec.

Protein identification and label-free quantification

Acquired MS spectra were imported into Progenesis software (version 2.5 Nonlinear Dynamics, Waters and analyzed as previously described [42,43]. After alignment, peak picking, exclusion of features with charge of 1 and >7 and normalization, spectra were exported as Mascot Generic files and searched against the Ensembl Horse database (Version 78) with Mascot (Matrix Science, Version 2.4.1). Peptide assignment was reimported to Progenesis Software. All unique peptides allocated to a protein were considered for quantification. Only proteins quantified with at least two peptides were included for further analysis. Abundances in individual samples were calculated by adding the single abundances of the respective peptides. Protein ratios between septin 7- or DOCK8-IP samples and the respective isotype control samples were determined by dividing these abundances. Data of DOCK8 interaction proteomics was analyzed with gene ranker (Genomatix version 3.7) for enrichment of canonical signal transduction pathways, using orthologous genes.

Western blots

PBL were lysed in lysis buffer (9 M Urea, 2 M Thiourea, 1% Dithioerythritol, 4% CHAPS, 2.5 µM EDTA) and Laemmli-buffer was added. Co-IP-eluates were just mixed with Laemmli-buffer before gel-electrophoresis. Proteins were separated by SDS-page on 8-10% gels and blotted onto 8.5 x 6.0 cm PVDF membranes (GE Healthcare). To prevent unspecific

binding, membranes were blocked with 4% BSA or 1% PVP-T. After washing, blots were incubated with rat anti-septin 7 monoclonal antibody (clone 19A4, self-made; neat), anti-DOCK8 (rabbit polyclonal, Santa Cruz Biotechnology; 1:1000), anti-ILK (mouse monoclonal, Santa Cruz Biotechnology; 1:1000) and anti-beta actin (mouse, monoclonal, Sigma-Aldrich; 1:50000) to control equal loading at 4°C overnight. Secondary antibodies were taken respectively. HRP-conjugated anti-rabbit IgG antibody (Cell Signaling Technology, Darmstadt, Germany; 1:10000), HRP-conjugated anti-rat IgG 2c antibody (1:8000) or HRP-conjugated anti-mouse IgG antibody (Sigma-Aldrich; 1:5000) were used for incubation at RT for one hour. After six washing steps, signaling was detected by enhanced chemoluminescence on X-ray film (SUPER-2000G ortho, Fuji; Christiansen, Planegg, Germany). Quantification of western blot signals was achieved by using open source Image J software https://imagej.net/Welcome. All abundances were normalized to respective beta actin signals.

Analysis of DOCK8 expression by flow cytometry

Staining was performed with anti-equine CD4 (mouse IgG1 monoclonal, Bio-Rad AbD Serotec, Puchheim, Germany; 1:100), PE-conjugated anti-equine CD8 (mouse IgG 2a monoclonal, Bio-Rad AbD Serotec; 1:10) and anti-equine B cells (clone CVS 41, monoclonal mouse IgG anti-horse Ig light chain, Bio-Rad AbD Serotec; 1:10) antibodies, diluted in FACS staining buffer (1% BSA + 0,001% NaN_3 in PBS). Staining with anti-DOCK8 antibody (rabbit polyclonal, Santa Cruz; 1:10) was performed after permeabilization of cells (BD Cytofix/Cytoperm fixation/permeabilization kit; BD Biosciences, Heidelberg, Germany). For all stainings, respective isotype controls were used. Respective secondary antibodies anti-mouse IgG1 PE, anti-mouse IgG PE (both Santa Cruz Biotechnology; 1:300) and anti-rabbit IgG Alexa 488 antibody (Invitrogen, Karlsruhe, Germany; 1:400) were added. Cells were fixed in 1% PFA diluted in staining buffer and stored at 4°C until further processing. On FACS Canto II, measurement of cells was performed with FACS Diva Software

(BD Biosciences). Further analysis of flow cytometry data was performed using open source Flowing Software 2.5.1 http://flowingsoftware.btk.fi/ (Perttu Terho, Turku Centre for Biotechnology, Finland).

Analysis of cell apoptosis

To investigate the effects of ILK expression differences on apoptosis, $1x10^7$ PBL from healthy and ERU cases were cultured in RPMI containing 6% fetal bovine serum (both PAN-Biotech). To compare apoptosis and necrosis between PBL of healthy controls and ERU horses, the Annexin V FITC Apoptosis Detection Kit (Sigma-Aldrich) was used on $1x10^5$ cells in a 96-well-plate. Cells were incubated with 2 µl Annexin V-FITC and 8 µl propium iodide (PI) for 10 minutes. The amount of apoptotic (annexin V positive) und necrotic cells (PI positive) was measured immediately after incubation time by using flow cytometry.

Statistics

For determination of Gaussian distribution, Kolmogorow-Smirnow (KS) test was used. If KS test was significant ($p \leq 0.05$; normal distribution), student's *t*-test was used for statistical analysis, if KS test was not significant ($p > 0.05$; no normal distribution) statistics were performed using Mann-Whitney test. Statistical comparisons of DOCK8 expression intensities in lymphocyte subsets were performed by using student's *t*-test. For comparison of DOCK8 expression intensity in healthy controls, DOCK8 geo MFI values were presented as means ± SD, for comparing DOCK8 expression in healthy and diseased specimen, controls were set to a 100% ± SD. Statistical analyses of DOCK8 expression intensity differences and ILK expression intensity differences in western blots as well as the comparison of apoptosis and necrosis rates were performed by using Mann-Whitney-test. In both tests, statistical probabilities were considered significant at $p \leq 0.05$.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

ACKNOWLEDGMENTS

This work was supported by a grant from the Deutsche Forschungsgemeinschaft DFG DE 719/4-3 (to C.D.). The authors would like to thank Hartmut Gerhards and Lutz S. Göhring as well as the staff of the Equine Clinic at LMU Munich for providing blood samples.

AUTHOR CONTRIBUTIONS

C.D. conceived, designed, performed and analyzed the experiments and supervised the project; M.S., S.H., C.W. and K.K. performed the experiments; M.S., S.H., C.W., R.D. and K.K. analyzed the data; S.H. contributed reagents, materials and analysis tools; E.K. produced antibodies; M.S. and C.D. wrote the manuscript. All authors critically read the manuscript and approved the final version to be published.

COMPETING INTERESTS

The authors declare that they have no competing financial interests.

REFERENCES

1 Menon, M. B. *et al.* Genetic deletion of SEPT7 reveals a cell type-specific role of septins in microtubule destabilization for the completion of cytokinesis. *PLoS Genet* **10**, e1004558, doi:10.1371/journal.pgen.1004558 (2014).

2 Gilden, J. K., Peck, S., Chen, Y. C. & Krummel, M. F. The septin cytoskeleton facilitates membrane retraction during motility and blebbing. *J Cell Biol* **196**, 103-114, doi:10.1083/jcb.201105127 (2012).

3 Mostowy, S. & Cossart, P. Septins: the fourth component of the cytoskeleton. *Nat Rev Mol Cell Biol* **13**, 183-194, doi:10.1038/nrm3284 (2012).

4 Kinoshita, M., Field, C. M., Coughlin, M. L., Straight, A. F. & Mitchison, T. J. Self- and actin-templated assembly of Mammalian septins. *Dev Cell* **3**, 791-802 (2002).

5 Kinoshita, M. Assembly of mammalian septins. *J Biochem* **134**, 491-496 (2003).

6 Sirajuddin, M. *et al.* Structural insight into filament formation by mammalian septins. *Nature* **449**, 311-315, doi:10.1038/nature06052 (2007).
7 Degroote, R. L. *et al.* Unraveling the equine lymphocyte proteome: differential septin 7 expression associates with immune cells in equine recurrent uveitis. *PLoS One* **9**, e91684, doi:10.1371/journal.pone.0091684 (2014).
8 Deeg, C. A. *et al.* Equine recurrent uveitis--a spontaneous horse model of uveitis. *Ophthalmic Res* **40**, 151-153, doi:10.1159/000119867 (2008).
9 Gilger, B. C. *et al.* Characterization of T-lymphocytes in the anterior uvea of eyes with chronic equine recurrent uveitis. *Vet Immunol Immunopathol* **71**, 17-28 (1999).
10 Deeg, C. A. *et al.* Uveitis in horses induced by interphotoreceptor retinoid-binding protein is similar to the spontaneous disease. *Eur J Immunol* **32**, 2598-2606, doi:10.1002/1521-4141(200209)32:9<2598::AID-IMMU2598>3.0.CO;2-# (2002).
11 Tooley, A. J. *et al.* Amoeboid T lymphocytes require the septin cytoskeleton for cortical integrity and persistent motility. *Nat Cell Biol* **11**, 17-26, doi:10.1038/ncb1808 (2009).
12 Deeg, C. A. *et al.* Immunopathology of recurrent uveitis in spontaneously diseased horses. *Exp Eye Res* **75**, 127-133 (2002).
13 Deeg, C. A., Reese, S., Gerhards, H., Wildner, G. & Kaspers, B. The uveitogenic potential of retinal S-antigen in horses. *Invest Ophthalmol Vis Sci* **45**, 2286-2292 (2004).
14 Serrao, V. H. *et al.* Promiscuous interactions of human septins: the GTP binding domain of SEPT7 forms filaments within the crystal. *FEBS Lett* **585**, 3868-3873, doi:10.1016/j.febslet.2011.10.043 (2011).
15 Kim, M. S., Froese, C. D., Xie, H. & Trimble, W. S. Uncovering principles that control septin-septin interactions. *J Biol Chem* **287**, 30406-30413, doi:10.1074/jbc.M112.387464 (2012).
16 Okada, S. *et al.* Daughter cell identity emerges from the interplay of Cdc42, septins, and exocytosis. *Dev Cell* **26**, 148-161, doi:10.1016/j.devcel.2013.06.015 (2013).
17 Randall, K. L. *et al.* DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. *J Exp Med* **208**, 2305-2320, doi:10.1084/jem.20110345 (2011).
18 Zhang, Q. *et al.* DOCK8 regulates lymphocyte shape integrity for skin antiviral immunity. *J Exp Med* **211**, 2549-2566, doi:10.1084/jem.20141307 (2014).
19 Jabara, H. H. *et al.* DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. *Nat Immunol* **13**, 612-620, doi:10.1038/ni.2305 (2012).
20 Pai, S. Y. *et al.* Flow cytometry diagnosis of dedicator of cytokinesis 8 (DOCK8) deficiency. *J Allergy Clin Immunol* **134**, 221-223, doi:10.1016/j.jaci.2014.02.023 (2014).
21 Hauck, S. M., Lepper, M. F., Hertl, M., Sekundo, W. & Deeg, C. A. Proteome dynamics in biobanked horse peripheral blood derived lymphocytes (PBL) with induced autoimmune uveitis. *Proteomics*, doi:10.1002/pmic.201700013 (2017).
22 Degroote, R. L. *et al.* Altered expression of talin 1 in peripheral immune cells points to a significant role of the innate immune system in spontaneous autoimmune uveitis. *J Proteomics* **75**, 4536-4544, doi:10.1016/j.jprot.2012.01.023 (2012).
23 Liu, E. *et al.* Targeted deletion of integrin-linked kinase reveals a role in T-cell chemotaxis and survival. *Mol Cell Biol* **25**, 11145-11155, doi:10.1128/MCB.25.24.11145-11155.2005 (2005).
24 Zhang, N. *et al.* The requirement of SEPT2 and SEPT7 for migration and invasion in human breast cancer via MEK/ERK activation. *Oncotarget* **7**, 61587-61600, doi:10.18632/oncotarget.11402 (2016).
25 Janssen, E. *et al.* A DOCK8-WIP-WASp complex links T cell receptors to the actin cytoskeleton. *J Clin Invest* **126**, 3837-3851, doi:10.1172/JCI85774 (2016).
26 Aydin, S. E. *et al.* DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients. *J Clin Immunol* **35**, 189-198, doi:10.1007/s10875-014-0126-0 (2015).
27 Randall, K. L. *et al.* Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. *Nat Immunol* **10**, 1283-1291, doi:10.1038/ni.1820 (2009).

28 Ham, H. *et al.* Dedicator of cytokinesis 8 interacts with talin and Wiskott-Aldrich syndrome protein to regulate NK cell cytotoxicity. *J Immunol* **190**, 3661-3669, doi:10.4049/jimmunol.1202792 (2013).
29 Jing, H. *et al.* Somatic reversion in dedicator of cytokinesis 8 immunodeficiency modulates disease phenotype. *J Allergy Clin Immunol* **133**, 1667-1675, doi:10.1016/j.jaci.2014.03.025 (2014).
30 Kearney, C. J., Randall, K. L. & Oliaro, J. DOCK8 regulates signal transduction events to control immunity. *Cell Mol Immunol* **14**, 406-411, doi:10.1038/cmi.2017.9 (2017).
31 Al-Herz, W. *et al.* Clinical, immunologic and genetic profiles of DOCK8-deficient patients in Kuwait. *Clin Immunol* **143**, 266-272, doi:10.1016/j.clim.2012.03.002 (2012).
32 Alsum, Z. *et al.* Clinical, immunological and molecular characterization of DOCK8 and DOCK8-like deficient patients: single center experience of twenty-five patients. *J Clin Immunol* **33**, 55-67, doi:10.1007/s10875-012-9769-x (2013).
33 Janssen, E. *et al.* Dedicator of cytokinesis 8-deficient patients have a breakdown in peripheral B-cell tolerance and defective regulatory T cells. *J Allergy Clin Immunol* **134**, 1365-1374, doi:10.1016/j.jaci.2014.07.042 (2014).
34 Deeg, C. A. *et al.* CRALBP is a highly prevalent autoantigen for human autoimmune uveitis. *Clin Dev Immunol* **2007**, 39245, doi:10.1155/2007/39245 (2007).
35 Deeg, C. A. *et al.* Identification and functional validation of novel autoantigens in equine uveitis. *Mol Cell Proteomics* **5**, 1462-1470, doi:10.1074/mcp.M500352-MCP200 (2006).
36 Boos, A. C. *et al.* Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern. *Allergy* **69**, 943-953, doi:10.1111/all.12416 (2014).
37 Rahikainen, R. *et al.* Mechanical stability of talin rod controls cell migration and substrate sensing. *Sci Rep* **7**, 3571, doi:10.1038/s41598-017-03335-2 (2017).
38 Degroote, R. L. *et al.* Expression changes and novel interaction partners of talin 1 in effector cells of autoimmune uveitis. *J Proteome Res* **12**, 5812-5819, doi:10.1021/pr400837f (2013).
39 Ahmed, A. U., Sarvestani, S. T., Gantier, M. P., Williams, B. R. & Hannigan, G. E. Integrin-linked kinase modulates lipopolysaccharide- and Helicobacter pylori-induced nuclear factor kappaB-activated tumor necrosis factor-alpha production via regulation of p65 serine 536 phosphorylation. *J Biol Chem* **289**, 27776-27793, doi:10.1074/jbc.M114.574541 (2014).
40 McDonald, P. C., Fielding, A. B. & Dedhar, S. Integrin-linked kinase--essential roles in physiology and cancer biology. *J Cell Sci* **121**, 3121-3132, doi:10.1242/jcs.017996 (2008).
41 Nho, R. S. *et al.* Role of integrin-linked kinase in regulating phosphorylation of Akt and fibroblast survival in type I collagen matrices through a beta1 integrin viability signaling pathway. *J Biol Chem* **280**, 26630-26639, doi:10.1074/jbc.M411798200 (2005).
42 Hauck, S. M. *et al.* Label-free LC-MSMS analysis of vitreous from autoimmune uveitis reveals a significant decrease in secreted Wnt signalling inhibitors DKK3 and SFRP2. *J Proteomics* **75**, 4545-4554, doi:10.1016/j.jprot.2012.04.052 (2012).
43 Hauck, S. M. *et al.* Deciphering membrane-associated molecular processes in target tissue of autoimmune uveitis by label-free quantitative mass spectrometry. *Mol Cell Proteomics* **9**, 2292-2305, doi:10.1074/mcp.M110.001073 (2010).

FIGURES AND FIGURE LEGENDS



Fig. 1: Septin 7 interacted with DOCK8 in equine PBL. Representative western blots of immunoprecipitations of septin 7 (A) and DOCK8 (B). DOCK8 was detected at 190 kDA in input lysates of PBL (input PBL) as well as after immunoprecipitation of septin 7 (A). Septin 7 was detected at 49 kDA in input lysates of PBL (input PBL) as well as after immunoprecipitation of DOCK8, verifying an interaction between these two proteins. In respective isotype controls (rb IgG) and blank (IP buffer), septin 7 was not detected.



Fig. 2: Characterization of DOCK8 expression in horse lymphocytes. (A) Representative DOCK8 expression in different lymphocyte subsets. Flow cytometry analyses demonstrate that DOCK8 is expressed in $CD4^+$ T cells, $CD8^+$ T cells and in B cells (white histograms) with high intensity. White histograms represent specific stainings, grey histograms represent respective isotype controls. Y-axis show the amount of cells included in measurement; x-axis show the intensity of DOCK8 staining. (B) Statistical analyses of geo mean fluorescence intensity of DOCK8 expression in lymphocyte subsets of 12 healthy controls. While there was no difference between DOCK8 expression intensity in $CD4^+$ T cells (white column) and $CD8^+$ T cells (light grey column), DOCK8 was significantly higher (* = $p \leq 0.05$) expressed in B cells (dark grey column) compared to T cells.



Fig. 3: Diminished DOCK8 protein levels in PBL of ERU cases. (A) Representative signal abundances of DOCK8 in PBL of controls (left panel) and ERU (right panel) detected by western blot. Compared to healthy controls (n=16), DOCK8 levels in ERU PBL (n=36) were significantly (*** = $p \leq 0.001$) decreased to 63% of physiological expression rate (set to a 100%). Protein abundances of DOCK8 were normalized to beta actin (signals shown below). (B) Statistical analysis of DOCK8 expression differences in lymphocyte subsets of healthy controls (white bars; n=13) and ERU cases (grey bars; n=12). DOCK8 expression intensity (geo MFI) was decreased in all lymphocyte subsets of ERU cases. In $CD8^+$ T cells, no considerable DOCK8 expression difference between control PBL and ERU cases could be detected, whereas in $CD4^+$ T cells of ERU horses, geo MFI was reduced to 85% compared to healthy controls. In B cells of autoimmune cases, a significant decrease of DOCK8 geo MFI to 57% was detected (* = $p \leq 0.05$).



Fig. 4: ILK expression in lymphocytes was significantly increased in diseased state and coincidented with increased cell survival. (A) Significantly increased ILK protein levels in ERU cases (n=33) compared to healthy controls (n=18) were verified and quantified by western blots (** = $p \leq 0.01$). ILK intensities were normalized to beta actin abundances on respective blots. Representative signal abundances are shown above respective columns. (B) PBL of healthy (biological n=4, technical replicates n=2) and ERU horses (biological replicates n=6), which constitutively differed in ILK expression were cultured at 37°C for 72 hours. Apoptosis rate was determined by measuring the amount of annexin V positive cells in flow cytometry. ERU horses (grey column), expressing ILK significantly higher (1.5-fold), showed a highly

significantly reduced amount of apoptotic cells compared to healthy controls (white column) (** = $p \leq 0.01$). (C) In contrast, necrosis rate of lymphocytes, determined by the amount of PI positive cells, was not different between healthy controls (white column) and ERU cases (grey bar).

Protein name	Gene name	Accession	Enrichment factor
Actin related protein 2/3 complex, subunit 2, 34kDa	ARPC2	ENSECAP00000009522	**3464,2**
Histone H2A	LOC100053378	ENSECAP00000001117	**101,3**
Cell division cycle 42	CDC42	ENSECAP00000003324	**76,6**
Capping protein (actin filament) muscle Z-line, alpha 1	CAPZA1	ENSECAP00000014750	**71,3**
Myosin, light chain 6, alkali, smooth muscle and non-muscle	MYL6	ENSECAP00000016002	**69,2**
Actin, cytoplasmic 2	ACTB	ENSECAP00000016124	**51,8**
Septin 6	SEP6	ENSECAP00000021088	**48,5**
Histone cluster 1, H2bj	HIST1H2BJ	ENSECAP00000001004	**46,8**
Vimentin	VIM	ENSECAP00000004638	**41,4**
Fibrinogen alpha chain	FGA	ENSECAP00000008007	**40,8**
C-reactive protein, pentraxin-related	CRP	ENSECAP00000022415	**40,7**
Actinin, alpha 1	ACTN1	ENSECAP00000017987	**40,3**
Septin 7	SEP7	ENSECAP00000020433	**36,0**
Dedicator of cytokinesis 8	DOCK8	ENSECAP00000010583	**32,2**
Myosin IG	MYO1G	ENSECAP00000016084	**28,2**
Flotillin 2	FLOT2	ENSECAP00000010141	**23,5**
Protein S100-A8	S100A8	ENSECAP00000007199	**22,7**
Tropomodulin 3 (ubiquitous)	TMOD3	ENSECAP00000018986	**20,8**
Cathepsin G	CTSG	ENSECAP00000003203	**20,4**
Septin 2	SEP2	ENSECAP00000015383	**18,8**

Table 1: Interacting proteins of septin 7 in PBL of healthy controls. List of septin 7 interactors with enrichment factor ≥ 18 detected by co-immunoprecipitation and identified by LC-MS/MS mass spectrometry. Column 1 (Protein name) shows name of protein. Column 2 (Gene name) shows gene name of identified protein. Column 3 (Accession) shows matching protein accession number, as listed in Ensembl Horse protein database (http://www.ensembl.org/Equus_caballus/Info/Index). Column 4 (Enrichment factor) shows the ratio of normalized protein abundance from enrichment compared to respective isotype controls.

Signaling pathway	*p*-value	No. of proteins observed	List of observed proteins (gene symbols)
ARP2 Actin Related Protein 2 Homolog (Yeast)	3,85E-08	6	ACTR2, GSN, VCL, ACTB, ARPC4, ACTR3
Small GTP-binding Protein RAC	3,13E-04	8	ACTR2, FERMT3, RSU1, DOCK8, CORO1C, IQGAP1, C1QA, PARVB
Myosin light chain kinase	6,35E-04	4	ACTN1, MYO18A, MYH10, MYL9

Table 2: Overrepresented signaling pathways of DOCK8 interacting proteins in PBL of healthy controls. List of the top 3 significantly (p-value) enriched signaling pathways containing DOCK8-interacting proteins enriched in healthy PBL (≥ 2 peptide counts; enrichment factor ≥ 4) analyzed by Genomatix (version 3.7).

Signaling pathway	*p*-value	No. of proteins observed	List of observed proteins (gene symbols)
ARP2 Actin Related Protein 2 Homolog (Yeast)	8,39E-06	6	VCL, ARPC4, CAPZA1, ACTR3, GSN, ACTB
Integrin	3,87E-04	12	LGALS3BP, ITGB3, VCL, FLNA, FN1, C3, TRF, VWF, ACTN1, TLN1, ILK, C1QA
Cofilin	1,44E-03	8	MYO9B, HSPB1, SEPT7, NEXN, PHB, GSN, SEPT2, ACTB

Table 3: Overrepresented signaling pathways of DOCK8 interacting proteins in PBL of ERU cases. List of the top 3 significantly (p-value) enriched signaling pathways containing DOCK8-interacting proteins enriched in ERU PBL (≥ 2 peptide counts; enrichment factor ≥ 4) analyzed by Genomatix (version 3.7).